NEW YORK--(BUSINESS WIRE)--Kirby McInerney LLP is investigating potential claims against the Board of Directors of BioClinica, Inc. (“BioClinica” or the “Company”) (NASDAQ: BIOC) related to the proposed acquisition of the Company by JLL Partners, Inc., a private equity firm. Under the terms of the agreement, JLL Partners will commence a cash tender offer to purchase all of BioClinica’s common stock for $7.25 per share, valuing the Company at approximately $123 million.
The investigation concerns whether the BioClinica Board of Directors violated its fiduciary duties by agreeing to this transaction and whether the proposed $7.25 per share consideration adequately values BioClinica shares. The offer price represents a 19% premium to the closing price of BioClinica shares the day prior to the announcement. At least one analyst has a price target for the Company’s stock of $9.00 per share, 24% above the offer price.
If you are a BioClinica shareholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at firstname.lastname@example.org, or by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form.
Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.